Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-17
2006-01-17
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S250000, C514S280000, C544S233000, C544S342000, C546S048000
Reexamination Certificate
active
06987109
ABSTRACT:
The invention provides compounds of formula I:whereinA, B, W, Y, Z, and R1have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for treating cancer using compounds of formula I.
REFERENCES:
patent: 2915523 (1959-12-01), Moore et al.
patent: 2981731 (1961-04-01), Moore et al.
patent: 2985661 (1961-05-01), Hien et al.
patent: 3267107 (1966-08-01), Sallay
patent: 3272707 (1966-09-01), Tedeschi
patent: 3449330 (1969-06-01), Guglielmetti et al.
patent: 3538097 (1970-11-01), Lowe et al.
patent: 3542782 (1970-11-01), Houlihan et al.
patent: 3849561 (1974-11-01), Junzo et al.
patent: 3884911 (1975-05-01), Shimada et al.
patent: 3912740 (1975-10-01), Zee-Chang et al.
patent: 4749708 (1988-06-01), Maroko
patent: 4761417 (1988-08-01), Maroko et al.
patent: 4761477 (1988-08-01), Ikekawa et al.
patent: 4925943 (1990-05-01), Kanmacher et al.
patent: 4980344 (1990-12-01), Maroko
patent: 5106863 (1992-04-01), Hajos et al.
patent: 5126351 (1992-06-01), Luzzio et al.
patent: 5153178 (1992-10-01), Maroko
patent: 5190753 (1993-03-01), Behrens et al.
patent: 5244903 (1993-09-01), Wall et al.
patent: 5318976 (1994-06-01), Luzzi et al.
patent: 5639759 (1997-06-01), Magolda et al.
patent: 5646283 (1997-07-01), Suzuki et al.
patent: 5767142 (1998-06-01), LaVoie et al.
patent: 5770617 (1998-06-01), LaVoie et al.
patent: 5807874 (1998-09-01), LaVoie et al.
patent: 5981541 (1999-11-01), LaVoie et al.
patent: 6140328 (2000-10-01), LaVoie et al.
patent: 6509344 (2003-01-01), Cushman et al.
patent: 6740650 (2004-05-01), LaVoie et al.
patent: 2004/0110760 (2004-06-01), LaVoie et al.
patent: 2005/0009824 (2005-01-01), LaVoie et al.
patent: 2005/0009825 (2005-01-01), LaVoie et al.
patent: 2005/0010046 (2005-01-01), LaVoie et al.
patent: 0108147 (1984-05-01), None
patent: 0496634 (1992-07-01), None
patent: 2108955 (1983-05-01), None
patent: 1530628 (1989-12-01), None
patent: WO-92/21661 (1992-12-01), None
patent: WO-96/36612 (1996-11-01), None
patent: WO-97/29106 (1997-08-01), None
patent: WO-98/12181 (1998-03-01), None
patent: WO-98/31673 (1998-07-01), None
patent: WO-99/31067 (1999-06-01), None
patent: WO-00/21537 (2000-04-01), None
patent: WO-01/32631 (2001-05-01), None
patent: WO-03/041660 (2003-05-01), None
patent: WO-03/047505 (2003-06-01), None
patent: WO-2004/014918 (2004-02-01), None
Denny, Expert Opin.Emerg. Drugs vol. 9(1), p. 105-133 (2004).
Aguirre, J. M., et al., “Reaction of 1,2-diarylethylamides with ethyl polyphosphate(EPP): correlation of the von Braun, Ritter and Bischler-Napieralski reactions.”,Chemical Abstracts, 111(13), Abstract No. 115004, (1989), 646.
Akiyama, Shin-Ichi, et al., “Isolation and Genetic Characterization of Human KB Cell Lines Resistant to Multiple Drugs”,Somatic Cell and Molecular Genetics, 11(2), (1985), 117-126.
Andoh, Toshiwo, et al., “Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I”,Proceedings of the National Academy of Sciences USA, 84(16), (1987), 5565-5569.
Andoh, Toshiwo, et al., “Drug resistance mechanisms of topoisomerase I drugs”,Advances in Pharmacology, vol. 29B, DNA Topoisomerases: Topoisomerase- Targeting Drugs, (1994), 93-103.
Arumugam, N., et al., “Synthesis of 7,8-Benzophenanthridines”,Indian Journal of Chemistry, vol. 12, (1974), 664-667.
Badia, Dolores, et al., “Silicon-mediated isoquinoline synthesis: preparation and stereochemical characterization of 4-hydroxy-3-phenylisoquinolines”,Chemical Abstracts, 117(13), Abstract No. 131034, (1992), 730.
Baezner, C., et al., “Uberfuhrung von o-nitro- und o,p-dinitro-benzylchlorid in acridinderivate”,Berichte der Deutschen Chemischen Gesellschaft, 39, English Title—Conversion of o-nitro and o,p-dinitrobenzylchlroide into acridinic derivatives, (1906), 2438-2447.
Baezner, Carlo, “Uberfuhrung von o-nitro-und o, p-dinitro-benzylchlorid in acridinderivate”,Berichte der Deutschen Chemischen Gesellschaft, 37, English Title—Conversion of o-nitrobenzyl chloride and o,p-dinitrobenzyl chloride into acridine derivatives, (1904), 3077-3083.
Bhakuni, D. S., et al., “Protoberberine Alkaloids”,The Alkaloids, vol. 28, Chapter 2, Academic Press, Inc., (1986), 95-181.
Bjornsti, Mary-Ann, et al., “Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin”,Cancer Research, 49, (1989), 6318-6323.
Bradsher, Charles K., et al., “alpha-Acyl-o-tolunitriles as intermediates in the preparation of 3-substituted isoquinolines and 1-amino-2-benzopyrylium derivatives”,Chemical Abstracts, 89(21), Abstract No. 89: 179810b, (1978), 590.
Brossi, Arnold, “Benzo[c]phenanthridine Alkaloids”,The Alkaloids, Chemistry and Pharmacology, vol. XXV, Academic Press, Inc., (1985), 178-199.
Buu-Hoi, N. P., et al., “Carcinogenic Nitrogen Compounds. XV. Polysubstituted Angular Benacridines and Benzophenarsazines”,Chemical Abstracts, 49(1), Abstract, col. 330, 10-Organic Chemistry, (1955), 329-330.
Buu-Hoi, N. G., et al., “The Chemistry of Carcinogenic Nitrogen Compounds. Part X. The Pfitzinger Reaction in the Synthesis of 1:2-Benzacridines”,Journal of the Chemical Society, Letchworth, GB, (1952), 279-281.
Buu-Hoi, N. G., “The chemistry of carcinogenic nitrogen compounds. Part V. Angular hydroxybenzacridines and hydroxydibenzacridines”,Journal of the Chemical Society, Letchworth GB, (1950), 2096-2099.
Carmichael, James, “Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing”,Cancer Research, 47, (1987), 936-42.
Chen, Allan Y., “A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures”,Cancer Research, 53(6), (1993), 1332-1337.
Chen, Allan Y., et al., “DNA Minor Groove-Binding Ligands: A Different Class of Mammalian DNA Topoisomerase I Inhibitors”,Proceedings of the National Academy of Sciences of the United States of America, 90, (1993),8131-8135.
Chen, Allan Y., et al., “DNA Topoisomerases: Essential Enzymes and Lethal Targets”,Annu. Rev. Pharmacol. Toxicol., 34, (1994), 191-218.
Cherif, Abdallah, et al., “N-(5,5-Diacetoxypent-1-yl)doxorubicin: a new intensely potent doxorubicin analogue”,Journal of Medicinal Chemistry, 35, (1992), 3208-3214.
Croisy-Delcey, M., et al., “Synthesis and Carcinogenic Activity of Oxidized Benzacridines: Potential Metabolites of the Strong Carcinogen 7-methylbenz[c]acridine and of the Inactive Isomer 12-methylbenz[a]acridine”,Chemical Abstracts, 98, Abstract No. 43798, (1983), 27-29.
Croisy-Delcey, M., et al., “Synthesis and carcinogenic activity of oxidized benzacridines: potential metabolites of the strong carcinogen 7-methylbenz[c]acridine and of the inactive isomer 12-methylbenz[a]acridine.”,Journal of Medicinal Chemistry, 26, (1983), 303-306.
Cushman, Mark, et al., “Synthesis and antitumor activity of structural analogues of the anticancer benzophenanthridine alkaloid fagaronine chloride”,Journal of Medicinal Chemistry, 28, (1985), 1031-1036.
Cushman, Mark, et al., “Synthesis of New Indeno[1,2-c]isoquinolines: Cytotoxic Non-Camptothecin Topoisomerase I Inhibitors”,Journal of Medicinal Chemistry, 43(20), (2000),3688-3698.
D'Arpa, Peter, et al., “Topoisomerase-targeting antitumor drugs”,Biochimica et Biophysica Acta, 989, (1989), 163-177.
Denizot, F., et al., “Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability”,Journal of Immunological Methods, 89,
LaVoie Edmond J.
Ruchelman Alexander L.
Raymond Richard L.
Rutgers The State University of New Jersey
Viksnins Harris & Padys PLLP
LandOfFree
Solubilized topoisomerase poison agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Solubilized topoisomerase poison agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solubilized topoisomerase poison agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3557859